Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

419 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Sakamoto Y, Nishina T, Inaki K, Kuwahara Y, Wada N, Suto F, Arita T, Sugihara M, Tsuchihashi Z, Saito K, Kojima A, Yamaguchi K. Shitara K, et al. Among authors: iwasa s. Nat Med. 2024 May 14. doi: 10.1038/s41591-024-02992-x. Online ahead of print. Nat Med. 2024. PMID: 38745009
The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology.
Kubo T, Sunami K, Koyama T, Kitami M, Fujiwara Y, Kondo S, Yonemori K, Noguchi E, Morizane C, Goto Y, Maejima A, Iwasa S, Hamaguchi T, Kawai A, Namikawa K, Arakawa A, Sugiyama M, Ohno M, Yoshida T, Hiraoka N, Yoshida A, Yoshida M, Nishino T, Furukawa E, Narushima D, Nagai M, Kato M, Ichikawa H, Fujiwara Y, Kohno T, Yamamoto N. Kubo T, et al. Among authors: iwasa s. ESMO Open. 2024 Apr;9(4):102981. doi: 10.1016/j.esmoop.2024.102981. Epub 2024 Apr 12. ESMO Open. 2024. PMID: 38613908 Free PMC article.
Correction to: Phase I study of the anti‑TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
Yamamoto N, Koyama T, Sato J, Yoshida T, Sudo K, Iwasa S, Kondo S, Yonemori K, Kawasaki A, Satake K, Shibata S, Shimizu T. Yamamoto N, et al. Among authors: iwasa s. Cancer Chemother Pharmacol. 2024 Mar 31. doi: 10.1007/s00280-024-04645-9. Online ahead of print. Cancer Chemother Pharmacol. 2024. PMID: 38556530 No abstract available.
Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program.
Kotani D, Takashima A, Kato T, Satoh T, Masuishi T, Komatsu Y, Shiozawa M, Esaki T, Izawa N, Takeuchi S, Bando H, Iwasa S, Hasegawa H, Yamaguchi T, Taniguchi H, Ushida Y, Oizaki T, Inoue C, Yoshino T. Kotani D, et al. Among authors: iwasa s. Clin Colorectal Cancer. 2024 Mar 9:S1533-0028(24)00022-7. doi: 10.1016/j.clcc.2024.02.002. Online ahead of print. Clin Colorectal Cancer. 2024. PMID: 38553360 Free article.
Circadian rhythms in CYP2A5 expression underlie the time-dependent effect of tegafur on breast cancer.
Yoshida Y, Fukuda T, Tanihara T, Nishikawa N, Iwasa S, Adachi S, Zaitsu O, Terada Y, Tsukamoto R, Shimoshikiryo H, Fukuoka K, Tsurusaki F, Hamamura K, Oyama K, Tsuruta A, Koyanagi S, Matsunaga N, Ohdo S. Yoshida Y, et al. Among authors: iwasa s. Biochem Biophys Res Commun. 2024 May 14;708:149813. doi: 10.1016/j.bbrc.2024.149813. Epub 2024 Mar 20. Biochem Biophys Res Commun. 2024. PMID: 38522403
Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
Yamamoto N, Koyama T, Sato J, Yoshida T, Sudo K, Iwasa S, Kondo S, Yonemori K, Kawasaki A, Satake K, Shibata S, Shimizu T. Yamamoto N, et al. Among authors: iwasa s. Cancer Chemother Pharmacol. 2024 Jan 11. doi: 10.1007/s00280-023-04627-3. Online ahead of print. Cancer Chemother Pharmacol. 2024. PMID: 38206370
419 results